NEWS HIGHLIGHTSMedia Articles Related to Fareston (Toremifene)
Secretary Sebelius Statement On New Breast Cancer Recommendations
Source: Health News from Medical News Today [2009.11.19]
HHS Secretary Kathleen Sebelius issued the following statement today on new breast cancer screening recommendations from the U.S. Preventive Services Task Force: "There is no question that the U.S. Preventive Services Task Force Recommendations have caused a great deal of confusion and worry among women and their families across this country. I want to address that confusion head on. The U.S.
Breast Cancer Campaign: New Breast Cancer Research Funding For Belfast
Source: Health News from Medical News Today [2009.11.19]
Individualised radiotherapy treatment based on a person's genetic make up could soon become a reality, according to Breast Cancer Campaign. Professor Kevin Prise from Queen's University Belfast has been awarded a three year project grant by the charity to study how genes are involved in the effectiveness of radiotherapy treatment for breast cancer.
Some Physicians Say New Breast Cancer Screening Guidelines Unlikely To Alter Their Practices
Source: Health News from Medical News Today [2009.11.19]
One day after the release of new breast cancer screening guidelines, many physicians and some medical groups are saying that they do not plan to adopt the new recommendations -- which represent a drastic change -- the New York Times reports (Belluck, New York Times, 11/18). The guidelines, released by the U.S.
Radiation Breakthrough Gives Breast Cancer Patients Hope In Single Dose
Source: Breast Cancer News From Medical News Today [2009.11.19]
A radiation breakthrough to treat breast cancer patients in one day, as opposed to the current average of six weeks, has arrived at Cancer Treatment Centers of America(R) (CTCA) in Philadelphia. CTCA will become the first in the country to offer this treatment option using the Novac7 technology from Rome, Italy.
Breast Cancer Screening: New Fuel for an Old War of Words and Data
Source: MedPageToday.com - medical news plus CME for physicians [2009.11.19]
A controversy that has alternately simmered and boiled for more than 40 years reached a flash point this week when the U.S. Preventive Services Task Force published recommendations for breast cancer screening with mammography.
Published Studies Related to Fareston (Toremifene)
Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study. [2008.04.10]
PURPOSE: Androgen-deprivation therapy (ADT) is associated with greater risk of incident coronary heart disease and hospital admission for myocardial infarction; treatment-related increases in serum lipids may contribute to greater cardiovascular disease risk. We evaluated the effects of toremifene, a selective estrogen-receptor modulator, on fasting serum lipid levels in men receiving ADT for prostate cancer... CONCLUSION: Toremifene significantly decreased total cholesterol, LDL cholesterol, and triglycerides, and increased HDL cholesterol in men receiving ADT for prostate cancer.
Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. [2008.01]
PURPOSE: We evaluated the effects of toremifene on bone mineral density, a surrogate for fracture risk, in men receiving androgen deprivation therapy for prostate cancer... CONCLUSIONS: Toremifene significantly increased hip and spine bone mineral density in men receiving androgen deprivation therapy for prostate cancer. The effect of toremifene on the fracture risk is being assessed in the ongoing randomized, controlled trial.
Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer. [2007.11.01]
PURPOSE: To compare time to progression (TTP) with a steroidal aromatase inhibitor (AI) atamestane (ATA) combined with toremifene (TOR; complete estrogen blockade) versus letrozole (LET) in receptor-positive advanced breast cancer (ABC)... CONCLUSION: TTP for patients receiving ATA + TOR was identical to that for patients receiving LET, representing the first endocrine therapy comparable to LET in ABC. Unlike in the Anastrozole, Tamoxifen, and Combined trial, addition of an antiestrogen did not decrease efficacy of the AI. Future studies of AIs in combination with more effective selective estrogen receptor modulators or selective receptor downregulators is warranted.
Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase IIB clinical trial. [2006.09]
PURPOSE: A randomized, double-blind, dose finding, placebo controlled, parallel group clinical study was done to determine the incidence of prostate cancer in men with high grade prostatic intraepithelial neoplasia treated with toremifene... CONCLUSIONS: Toremifene decreased the incidence of prostate cancer by 1 year and had a tolerability profile comparable to that of placebo in a high risk population.
Toremifene for premenstrual mastalgia: a randomised, placebo-controlled crossover study. [2006.06]
OBJECTIVE: To investigate the efficacy of toremifene in the treatment of premenstrual mastalgia... There was a 64% reduction in median pain scores in the toremifene-treated cycles compared with a 26% reduction in placebo-treated cycles.
Clinical Trials Related to Fareston (Toremifene)
Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer [Terminated]
Protocol 777-CLP-32 is the treatment and survival continuation protocol of Biomed 777-CLP-29,
and will continue to compare combined hormonal therapy using the experimental aromatase
inhibitor (AI) atamestane combined with the FDA-approved anti-estrogen toremifene
(Fareston®), to the single agent FDA-approved aromatase inhibitor letrozole (Femara®) for the
treatment of advanced breast cancer. The purpose of this study is to determine whether
maximal estrogen suppression achieved via the combination of atamestane, plus toremifene
(Fareston®), is more effective than letrozole (Femara®) in delaying the growth of breast
cancer.
The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer [Terminated]
The purpose of this study is to determine whether maximal estrogen suppression achieved via
the combination of an experimental drug, atamestane, plus an FDA-approved drug, toremifene
(Fareston®), is more effective than another approved drug, letrozole (Femara®), in delaying
the growth of breast cancer, and whether the side effects of the combined hormonal therapy
are different from the side effects of letrozole.
The Effect of Toremifene Treatment to the Magnetic Resonance Imaging (MRI) Findings in Premenstrual Mastalgia [Active, not recruiting]
The purpose of this study is to determine the effect of toremifene treatment to the MRI
findings of the breast in women suffering from premenstrual mastalgia.
Prostate Cancer Prevention Study for Men With High Grade PIN (Prostatic Intraepithelial Neoplasia) [Active, not recruiting]
The purpose of this study is to determine if toremifene citrate is effective and safe in the
prevention of prostate cancer in men who have been diagnosed with high grade prostatic
intraepithelial neoplasia (PIN).
Toremifene With or Without Atamestane in Treating Postmenopausal Women With Metastatic Breast Cancer [Terminated]
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Toremifene may fight
breast cancer by blocking the uptake of estrogen by the tumor cells. Atamestane may fight
breast cancer by blocking the production of estrogen. It is not yet known if toremifene is
more effective with or without atamestane.
PURPOSE: Randomized phase III trial to compare the effectiveness of toremifene with or
without atamestane in treating postmenopausal women who have metastatic breast cancer.
|
